Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation – a randomised trial

Patil, Vijay; Noronha, Vanita; Menon, Nandini; Mathrudev, Vijayalakshmi; Bhattacharjee, Atanu; Nawale, Kavita Prakash; Parekh, Deevyashali; Banavali, Shripad; Prabhash, Kumar

doi:10.1016/j.lansea.2023.100162

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the combination of MCT with antiangiogenic drugs could enhance the proapoptotic effects of chemotherapeutic agents on proliferating endothelial cells. Numerous studies have demonstrated that VEGF inhibitors or COX-2 inhibitors combined with MCT may be associated with survival benefits in patients with various cancers 147 - 149 . In a single-arm prospective clinical trial, the combination of the VEGF inhibitor bevacizumab and metronomic capecitabine and cyclophosphamide was found to be effective in advanced breast cancer 148 .…”

Section: Mct Combined With Other Therapiesmentioning

confidence: 99%

“…Similarly, a phase II trial demonstrated the effectiveness of bevacizumab combined with metronomic cyclophosphamide in patients with recurrent ovarian cancer 149 . However, in a phase III randomized trial, patients with head and neck cancer who received the adjuvant metronomic methotrexate and celecoxib (a COX-2 inhibitor) failed to experience improvements in PFS or overall survival (OS) 147 .…”

Section: Mct Combined With Other Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

Wu,

Zhou,

Chen

et al. 2024

Theranostics

View full text Add to dashboard Cite

Section: Mct Combined With Other Therapiesmentioning

confidence: 99%

Section: Mct Combined With Other Therapiesmentioning

confidence: 99%

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

Wu,

Zhou,

Chen

et al. 2024

Theranostics

View full text Add to dashboard Cite

“…Metronomic chemotherapy (the continuous and Am J Cancer Res 2024;14(3):1033-1051 low-dose administration of chemotherapeutic agents) was found to exert anti-angiogenic effects by reducing the expression of CD31 in the nude mouse tumor-bearing model of the OSCC cell line, HSC2 [9]. Metronomic adjuvant chemotherapy was shown to significantly improve the overall survival of patients with advanced OSCC in a randomized study in China [10], but not that of patients with advanced OSCC in a randomized study in India [11]. Therefore, the benefits of metronomic chemotherapy for OSCC remain controversial.…”

Section: Introductionmentioning

confidence: 99%

Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy

Kina

2024

Am J Cancer Res

View full text Add to dashboard Cite

Distant metastasis is an important prognostic factor for oral squamous cell carcinoma (OSCC). It involves the direct spread of tumor cells through blood vessels or via lymph nodes; however, there are currently no well-established treatments for its prevention in patients with OSCC. To investigate the impact of metronomic neoadjuvant chemotherapy on OSCC, we conducted a retrospective analysis of the efficacy of neoadjuvant chemotherapy with S-1 alone. Fifty-four patients underwent up-front surgery, while 106 received neoadjuvant chemotherapy with S-1 alone. A serious adverse event occurred in one of patient treated with neoadjuvant chemotherapy (1%); however, all patients underwent resection. The 5-year overall survival rate was higher with S-1 than with up-front surgery (96% vs. 81%, P = 0.002). Moreover, neoadjuvant chemotherapy significantly increased the overall survival rate of patients with poorly or moderately differentiated tumors, but not those with well-differentiated tumors. By analyzing a cohort of 523 head and neck squamous cell carcinoma (HNSCC) patients in the Cancer Genome Atlas, we identified genetic variants associated with histological differentiation. The frequency of pathogenic/likely pathogenic variants or deletions in 5 genes associated with HNSCC correlated with histological differentiation, some of which indicated the activation of the Wnt/β-catenin pathway in well-differentiated HNSCC. The vessel marker CD31 was highly expressed in poorly differentiated OSCC, whereas the anti-angiogenic molecule, LCN2, which is induced by the activation of the Wnt pathway, was highly expressed in well-differentiated OSCC. The present study showed that overall survival rates were higher in patients with poorly or moderately differentiated OSCC who received metronomic neoadjuvant chemotherapy, which was attributed to a difference in angiogenesis based on the characteristic landscape of pathogenic mutations according to histological differentiation.

show abstract

Metronomic adjuvant chemotherapy evaluation in locally advanced head and neck cancers post radical chemoradiation – a randomised trial

Cited by 2 publications

References 23 publications

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy

Contact Info

Product

Resources

About